Abstract
The aim of this study was to determine the prevalence of chronic disease and the risk factors for herpes zoster infection. In this case-control study medical records were collected from 55 patients who presented with herpes zoster and 54 patients in a control group who presented with gastroenterocolitis. Both groups were treated at the Clinic for Infectious Diseases, University Clinical Hospital Mostar from January, 2005 to December, 2010. When we compared the herpes zoster group with the control group, we did not demonstrate any significant difference in the overall prevalence of chronic diseases. However, the prevalence of diabetes and cancer was statistically higher when compared to the control group. A statistically significant difference in the number of cigarette smokers was not observed, whereas the number who consumed alcohol in the herpes zoster group was significantly higher compared to the control group. The correlation between alcohol and herpes zoster could help in solving the reactivation mechanism of VZV.
[1] Cohen J.I., The varicella-zoster virus genome, Curr Top Microbiol Immunol, 2010, 342, 1–14 DOI: 10.1007/82_2010_10 http://dx.doi.org/10.1007/82_2010_1010.1007/82_2010_10Search in Google Scholar
[2] Seward J., Jumaan A., VSV: persistence in the population, In: Arvin A., Campadelli-Fiume G., Mocarski E., Moore P. S., Roizman B., Whitley R. et al. (Eds), Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, Cambridge: Cambridge University Press, 2007 Search in Google Scholar
[3] Moffat J., Ku C.C., Zerboni L., Sommer M., Arvin A., VZV: pathogenesis and the disease consequences of primary infection, In: Arvin A., Campadelli-Fiume G., Mocarski E., Moore P. S., Roizman B., Whitley R. et al. (Eds), Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, Cambridge: Cambridge University Press, 2007 Search in Google Scholar
[4] Liesegang T.J., Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity, Ophthalmology, 2008, 115, S3–12 DOI: 10.1016/j.ophtha.2007.10.009 http://dx.doi.org/10.1016/j.ophtha.2007.10.00910.1016/j.ophtha.2007.10.009Search in Google Scholar
[5] Arvin A., Abendroth A., VZV: immunobiology and host response, In: Arvin A., Campadelli-Fiume G., Mocarski E., Moore P. S., Roizman B., Whitley R. et al. (Eds), Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, Cambridge: Cambridge University Press 2007 10.1017/CBO9780511545313Search in Google Scholar
[6] Brisson M., Edmunds W.J., Law B., Gay N.J., Walld R., Brownell M., et al., Epidemiology of varicella zoster virus infection in Canada and the United Kingdom, Epidemiol Infect, 2001, 127, 305–314 http://dx.doi.org/10.1017/S095026880100592110.1017/S0950268801005921Search in Google Scholar
[7] Glynn C., Crockford G., Gavaghan D., Cardno P., Price D., Miller J., Epidemiology of shingles, J R Soc Med, 1990, 83, 617–619 10.1177/014107689008301007Search in Google Scholar
[8] Wareham D.W., Breuer J., Herpes zoster, BMJ, 2007, 334, 1211–1215 DOI: 10.1136/bmj.39206.571042.AE http://dx.doi.org/10.1136/bmj.39206.571042.AE10.1136/bmj.39206.571042.AESearch in Google Scholar
[9] Liesegang T.J., Herpes zoster virus infection, Curr Opin Ophthalmol, 2004, 15, 531–536 http://dx.doi.org/10.1097/01.icu.0000143686.68103.4610.1097/01.icu.0000143686.68103.46Search in Google Scholar
[10] van Wijck A.J., Wallace M., Mekhail N., van Kleef M., Evidence-based interventional pain medicine according to clinical diagnoses. 17. Herpes zoster and post-herpetic neuralgia, Pain Pract, 2011, 11, 88–97 DOI: 10.1111/j.1533-2500.2010.00428.x http://dx.doi.org/10.1111/j.1533-2500.2010.00428.x10.1111/j.1533-2500.2010.00428.xSearch in Google Scholar
[11] Chidiac C., Bruxelle J., Daures J.P., Hoang-Xuan T., Morel P., Leplege A., et al., Characteristics of patients with herpes zoster on presentation to practitioners in France, Clin Infect Dis, 2001, 33, 62–69 DOI: 10.1086/320884 http://dx.doi.org/10.1086/32088410.1086/320884Search in Google Scholar
[12] Thomas S.L., Hall A.J., What does epidemiology tell us about risk factors for herpes zoster?, Lancet Infect Dis, 2004, 4, 26–33 http://dx.doi.org/10.1016/S1473-3099(03)00857-010.1016/S1473-3099(03)00857-0Search in Google Scholar
[13] Leung J., Harpaz R., Baughman A.L., Heath K., Loparev V., Vazquez M., et al., Evaluation of laboratory methods for diagnosis of varicella, Clin Infect Dis, 2010, 51, 23–32 DOI: 10.1086/653113 http://dx.doi.org/10.1086/65311310.1086/653113Search in Google Scholar PubMed
[14] Opstelten W., Eekhof J., Neven A.K., Verheij T., Treatment of herpes zoster, Can Fam Physician, 2008, 54, 373–377 Search in Google Scholar
[15] Alper B.S., Lewis P.R., Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia?, J Fam Pract, 2000, 49, 255–264 Search in Google Scholar
[16] Lancaster T., Silagy C., Gray S., Primary care management of acute herpes zoster: systematic review of evidence from randomized controlled trials, Br J Gen Pract, 1995, 45, 39–45 Search in Google Scholar
[17] Wood M.J., Johnson R.W., McKendrick M.W., Taylor J., Mandal B.K., Crooks J., A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster, N Engl J Med, 1994, 330, 896–900 DOI: 10.1056/NEJM199403313301304 http://dx.doi.org/10.1056/NEJM19940331330130410.1056/NEJM199403313301304Search in Google Scholar PubMed
[18] Berry J.D., Petersen K.L., A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster, Neurology, 2005, 65, 444–447 DOI: 10.1212/01.wnl.0000168259.94991.8a http://dx.doi.org/10.1212/01.WNL.0000168259.94991.8a10.1212/01.WNL.0000168259.94991.8aSearch in Google Scholar PubMed
[19] Schmader K., Herpes zoster in older adults, Clin Infect Dis, 2001, 32, 1481–1486 DOI: 10.1086/320169 http://dx.doi.org/10.1086/32016910.1086/320169Search in Google Scholar PubMed
[20] Schmader K., George L.K., Burchett B.M., Pieper C.F., Hamilton J.D., Racial differences in the occurrence of herpes zoster, J Infect Dis, 1995, 171, 701–704 http://dx.doi.org/10.1093/infdis/171.3.70110.1093/infdis/171.3.701Search in Google Scholar PubMed
[21] Okamoto S., Hata A., Sadaoka K., Yamanishi K., Mori Y., Comparison of varicella-zoster virus-specific immunity of patients with diabetes mellitus and healthy individuals, J Infect Dis, 2009, 200, 1606–1610 DOI: 10.1086/644646 http://dx.doi.org/10.1086/64464610.1086/644646Search in Google Scholar PubMed
[22] Strangfeld A., Listing J., Herzer P., Liebhaber A., Rockwitz K., Richter C., et al., Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents, JAMA, 2009, 301, 737–744 DOI: 10.1001/jama.2009.146 http://dx.doi.org/10.1001/jama.2009.14610.1001/jama.2009.146Search in Google Scholar PubMed
[23] Schuchter L.M., Wingard J.R., Piantadosi S., Burns W.H., Santos G.W., Saral R., Herpes zoster infection after autologous bone marrow transplantation, Blood, 1989, 74, 1424–1427 10.1182/blood.V74.4.1424.1424Search in Google Scholar
[24] Toyama N., Shiraki K., Society of the Miyazaki Prefecture D., Epidemiology of herpes zoster and its relationship to varicella in Japan: A 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture, J Med Virol, 2009, 81, 2053–2058 DOI: 10.1002/jmv.21599 http://dx.doi.org/10.1002/jmv.2159910.1002/jmv.21599Search in Google Scholar PubMed
[25] Joesoef R.M., Harpaz R., Leung J., Bialek S.R., Chronic medical conditions as risk factors for herpes zoster, Mayo Clinic proceedings Mayo Clinic, 2012, 87, 961–967 DOI: 10.1016/j.mayocp.2012.05.021 http://dx.doi.org/10.1016/j.mayocp.2012.05.02110.1016/j.mayocp.2012.05.021Search in Google Scholar PubMed PubMed Central
© 2013 Versita Warsaw
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
